ETLI:XETRA:XETRA-L&G Pharma Breakthrough UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 9.928

Change

-0.05 (-0.50)%

Market Cap

USD 0.02B

Volume

77.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-02 )

ETFs Containing ETLI:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.30% 43% F 46% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.30% 42% F 45% F
Trailing 12 Months  
Capital Gain -2.05% 14% F 22% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -2.05% 13% F 21% F
Trailing 5 Years  
Capital Gain 19.48% 41% F 46% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 19.48% 40% F 43% F
Average Annual (5 Year Horizon)  
Capital Gain 0.00% N/A N/A 29% F
Dividend Return 0.00% N/A N/A 28% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 11.48% N/A N/A 63% D
Risk Adjusted Return -0.01% N/A N/A 28% F
Market Capitalization 0.02B 12% F 11% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.